TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29153631

Group type: EXPERIMENTAL
Intervention: Brivaracetam 50mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brivaracetam 200mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brivaracetam 1000mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brivaracetam (all doses)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brivaracetam 50mg, 200mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brivaracetam (50-200mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Alprazolam (1.5mg, 3mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Levetiracetam (4000mg)
Number of subjects: 44
Study: 28324265

Group type: EXPERIMENTAL
Intervention: CMF+T
Number of subjects: 90

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 90
Study: 26639477

Group type: EXPERIMENTAL
Intervention: Micro emulsion formulation
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Gel formulation
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Ointment formulation
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo formulations
Number of subjects: 360
Study: 23742877

Group type: EXPERIMENTAL
Intervention: Aflibercept (6 mg/kg, intravenously every 3 weeks)
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Placebo (intravenously every 3 weeks)
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1224
Study: 20130535

Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18375897

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video plus counseling group
Number of subjects: 0
Study: 16538452

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 402
Study: 14615734

Group type: EXPERIMENTAL
Intervention: Asphyxiated newborn infants
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control neonates
Number of subjects: 58
Study: 10865186

Group type: EXPERIMENTAL
Intervention: C.E.S. (synthetic mixture of estrogens; 2 x 0.625 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Premarin (2 x 0.625 mg)
Number of subjects: 41
Study: 9354964

Group type: EXPERIMENTAL
Intervention: Cell wall‐associated proteins of Mycobacterium tuberculosis (SIHV) by ELISA
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control sera (healthy individuals)
Number of subjects: 86
Study: 8397986

Group type: EXPERIMENTAL
Intervention: Dentin bonding system that removed smear layer
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dentin bonding system that adhered to the dentin smear layer
Number of subjects: 44
Study: 2871960

Group type: EXPERIMENTAL
Intervention: Somatostatin (10 nmol/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg, intravenously)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg, intravenously)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7
Study: 30412061

Group type: EXPERIMENTAL
Intervention: Resource mindfulness (test group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stress mindfulness (active control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 26957418

Group type: EXPERIMENTAL
Intervention: Immediate stenting
Number of subjects: 140

Group type: COMPARATOR
Intervention: Delayed stenting (DS)
Number of subjects: 140
Study: 25686644

Group type: EXPERIMENTAL
Intervention: Rituximab (four weekly infusions of 375 mg/m(2))
Number of subjects: 313

Group type: COMPARATOR
Intervention: Rituximab + interferon‐α2a (3‐4.5 MIU daily for 5 weeks)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 313
Study: 24821568

Group type: EXPERIMENTAL
Intervention: peramivir
Number of subjects: 191

Group type: COMPARATOR
Intervention: zanamivir
Number of subjects: 191

Group type: COMPARATOR
Intervention: oseltamivir
Number of subjects: 191

Group type: COMPARATOR
Intervention: laninamivir
Number of subjects: 191
Study: 20671033

Group type: EXPERIMENTAL
Intervention: QRS-gated brachial artery diameter measurements
Number of subjects: 72

Group type: COMPARATOR
Intervention: Average brachial diameters over the entire R-R interval
Number of subjects: 72
Study: 18984252

Group type: EXPERIMENTAL
Intervention: Snoring severity score (SSS) = 4 or BMI = 26
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: BMI > or = 32
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: SSS > or = 7
Number of subjects: 211
Study: 16265663

Group type: EXPERIMENTAL
Intervention: Dornase alfa 7%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12946731

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 11061474

Group type: EXPERIMENTAL
Intervention: 500 microg beclomethasone dipropionate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: 20 microg endotoxin (control)
Number of subjects: 12
Study: 8742215

Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgical discectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chymopapain (first-line treatment)
Number of subjects: 60
Study: 1616080

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional analgesic therapy (intermittent intravenous morphine injections)
Number of subjects: 24
Study: 6091483

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g IV at start of anesthesia, followed by 1 g dose 24 hours later)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g IV at start of anesthesia, followed by 1.5 g every 12 hours for 2 days)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g IV at start of anesthesia)
Number of subjects: 512
Study: 30594365

Group type: EXPERIMENTAL
Intervention: 55,000 plants/ha
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 70,000 plants/ha
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 85,000 plants/ha
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 100,000 plants/ha
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Increasing planting population
Number of subjects: 28
Study: 30081667

Group type: EXPERIMENTAL
Intervention: Pre-K Mathematics intervention
Number of subjects: 0
Study: 26546051

Group type: EXPERIMENTAL
Intervention: Adjunct treatment with intravitreal and subtenons triamcinolone acetonide, oral flurbiprofen, and guttae prednisolone acetate 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adjunct treatment
Number of subjects: 40
Study: 24681717

Group type: EXPERIMENTAL
Intervention: MoodGYM (5-week computerized cognitive behavior therapy program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informational websites about mental health (control condition)
Number of subjects: 0
Study: 22965622

Group type: EXPERIMENTAL
Intervention: CVD prevention intervention arm
Number of subjects: 135

Group type: COMPARATOR
Intervention: Comparison arm focusing on increasing family cohesiveness, communication, and connectedness
Number of subjects: 135
Study: 20060229

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18044284

Group type: EXPERIMENTAL
Intervention: Intermittent bolus administration of cisatracurium (Group A, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion of cisatracurium (Group B, n = 30)
Number of subjects: 60
Study: 16047532

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 11896038

Group type: EXPERIMENTAL
Intervention: Acetaminophen (therapeutic dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10426647

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 600 microg misoprostol
Number of subjects: 60
Study: 7760614

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard epidural analgesia
Number of subjects: 197
Study: 1559504

Group type: EXPERIMENTAL
Intervention: Sunflower oil diet high in polyunsaturated fatty acids (13 E%, total fat 38%)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet high in monounsaturated fatty acids (16 E%, total fat 38%)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Baseline diet high in saturated fatty acids (19 E%, total fat 36%)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Recovery period (4 weeks)
Number of subjects: 59
Study: 4014617

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.75% in oxygen)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Entonox (50% nitrous oxide in oxygen)
Number of subjects: 32
Study: 29947141

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) three times per week for 4 weeks
Number of subjects: 30
Study: 29096877

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 100
Study: 26514957

Group type: EXPERIMENTAL
Intervention: Computer-assisted motivational intervention (CAMI)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Didactic educational counseling
Number of subjects: 572
Study: 24607801

Group type: EXPERIMENTAL
Intervention: Interferential current therapy (ICT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo-ICT
Number of subjects: 42
Study: 22670827

Group type: EXPERIMENTAL
Intervention: air-Q SP
Number of subjects: 60

Group type: COMPARATOR
Intervention: LMA-Unique
Number of subjects: 60
Study: 20418006

Group type: EXPERIMENTAL
Intervention: Continuous chest compressions (CCC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard CPR (30:2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Feedback (FB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No feedback (NFB)
Number of subjects: 64
Study: 18398944

Group type: EXPERIMENTAL
Intervention: QuantiFeron‐TB Gold In‐Tube assay (QFT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST)
Number of subjects: 101
Study: 15472009

Group type: EXPERIMENTAL
Intervention: Plantar vibration at 45 Hz
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Plantar vibration
Number of subjects: 18
Study: 12100113

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9759992

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 103
Study: 8172870

Group type: EXPERIMENTAL
Intervention: 57Fe
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 58Fe
Number of subjects: 9
Study: 3127483

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine 0.1%
Number of subjects: 30
Study: 30442284

Group type: EXPERIMENTAL
Intervention: TF‐TAVR
Number of subjects: 1204

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1204
Study: 27223846

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once-daily
Number of subjects: 0
Study: 25573349

Group type: EXPERIMENTAL
Intervention: Multiplex PCR (mPCR) performed as an addition to standard diagnostics
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no awareness of PCR result)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Study group (mPCR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no mPCR)
Number of subjects: 150
Study: 23149259

Group type: EXPERIMENTAL
Intervention: Keeping animals in the same group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Preventing direct contact with neighbouring cattle
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Maintaining dry bedding
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Maintaining a closed herd using quarantine procedures
Number of subjects: 77
Study: 20506355

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 18226725

Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nitrous oxide-oxygen mixture (E)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Morphine + Nitrous oxide-oxygen mixture (ME)
Number of subjects: 34
Study: 16995547

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 80
Study: 14570640

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study: 11048472

Group type: EXPERIMENTAL
Intervention: 300 mg sustained-release diltiazem
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5 mg ramipril
Number of subjects: 50
Study: 8905026

Group type: EXPERIMENTAL
Intervention: Doxorubicin (50, 60 mg/m2) followed by paclitaxel (155, 175 mg/m2) every 3 weeks
Number of subjects: 30
Study: 8418709

Group type: EXPERIMENTAL
Intervention: 400 IU/kg rHuEPO subcutaneously once a week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Iron only (Control)
Number of subjects: 24
Study: 3533292

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefazolin (Fowler's protocol)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with i.v. gentamycin or tobramycin and clindamycin or metronidazole
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 45
Study: 29324186

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) ingestion (600 mg·kg‐1) during recovery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLC) during recovery
Number of subjects: 20
Study: 24362634

Group type: EXPERIMENTAL
Intervention: CAF + PRF
Number of subjects: 22

Group type: COMPARATOR
Intervention: CAF + SCTG
Number of subjects: 22
Study: 22574589

Group type: EXPERIMENTAL
Intervention: Yishen Jiangzhuo Granule (YJG)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 20374985

Group type: EXPERIMENTAL
Intervention: Peer Support Technicians (PSTs) implementation
Number of subjects: 0
Study: 19120293

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elimination of cow's milk from infant feeding
Number of subjects: 0
Study: 15877709

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12665761

Group type: EXPERIMENTAL
Intervention: EUS (Endoscopic Ultrasound)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: EUS-based strategy
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 485
Study: 10323426

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver (20 minutes with 5-minute clamp-free interval)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Accumulated ischemic time longer than 120 minutes
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no Pringle maneuver)
Number of subjects: 112
Study: 8607507

Group type: EXPERIMENTAL
Intervention: naproxen sodium (660 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: acetaminophen (4000 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: naproxen sodium (660 mg/d) in subjects with endoscopic changes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: naproxen sodium (660 mg/d) in subjects without endoscopic damage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: initial mucin in subjects with endoscopic changes after naproxen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: initial hydrophobicity in subjects with endoscopic changes after naproxen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: initial pepsin in subjects with endoscopic changes after naproxen
Number of subjects: 30
Study: 2015153

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 46

Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both drugs (Clonidine 150 micrograms and Flunitrazepam 1 mg)
Number of subjects: 46
Study: 6116723

Group type: EXPERIMENTAL
Intervention: Gonococcal pilus vaccine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31151424

Group type: EXPERIMENTAL
Intervention: Whole image registration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ipsilateral registration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft tissue tumor registration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vertebral body registration
Number of subjects: 60
Study: 28787252

Group type: EXPERIMENTAL
Intervention: Interpersonally involving training program based on self‐determination theory principles
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 382
Study: 27058970

Group type: EXPERIMENTAL
Intervention: Learning Collaborative intervention (Phase 1, months 1-9)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait-list control group (Phase 1, months 1-9)
Number of subjects: 38
Study: 22902185

Group type: EXPERIMENTAL
Intervention: High dose B vitamins
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2056
Study: 21975348

Group type: EXPERIMENTAL
Intervention: JNJ-38431055 (2.5-800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-38431055 (in graded glucose infusion study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18268112

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 16998362

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 12
Study: 12710749

Group type: EXPERIMENTAL
Intervention: Low-abrasive air polishing powder
Number of subjects: 23

Group type: COMPARATOR
Intervention: Curets (positive control)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Subgingival plaque sampling alone (negative control)
Number of subjects: 23
Study: 10898693

Group type: EXPERIMENTAL
Intervention: Fluconazole and clarithromycin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluconazole and clarithromycin together
Number of subjects: 10
Study: 8985111

Group type: EXPERIMENTAL
Intervention: Injection of 50 units of botulinum toxin type A (BTX‐A) into the mid belly of the gastrocnemius muscle (distally at three sites)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Injection of 50 units of botulinum toxin type A (BTX‐A) into the proximal site near the muscular origin of the gastrocnemius muscle
Number of subjects: 17
Study: 1727998

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (0.15 mg/kg per dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 28
Study: 6319452

Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.5, 1.0, and 1.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (serotonin antagonist) pretreatment before fenfluramine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29032481

Group type: EXPERIMENTAL
Intervention: Transitioning Together program (8-week multi-family group psychoeducation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Transitioning Together program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control condition (waitlist)
Number of subjects: 41
Study: 28846787

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional osteotome
Number of subjects: 65
Study: 26652168

Group type: EXPERIMENTAL
Intervention: Continence promotion intervention
Number of subjects: 1000
Study: 23100457

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21247573

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) vaginal washing
Number of subjects: 502

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 502
Study: 18336635

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 16861420

Group type: EXPERIMENTAL
Intervention: BIS-guided remifentanil/propofol regimen
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clinically guided regimen (SAS group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BIS-guided regimen
Number of subjects: 54
Study: 12874612

Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure (HBP) measurement (5 days, four times daily)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Clinic blood pressure (CBP) measurement
Number of subjects: 411
Study: 11155608

Group type: EXPERIMENTAL
Intervention: Individualized professional support
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 51
Study: 9177389

Group type: EXPERIMENTAL
Intervention: 1 IU/m2/day GH
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 IU/m2/day GH
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 IU/m2/day GH
Number of subjects: 36

Group type: COMPARATOR
Intervention: GH (2 IU/m2/day) after 6 months of placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 36